NoviaHealth spins off from Synbiotic Health to focus on probiotic commercialization

NoviaHealth-spins-off-from-Synbiotic-Health-to-focus-on-probiotic-commercialization.jpg
© nadisja / Getty Images (Getty Images/iStockphoto)

There’s a new contract development and manufacturing organization (CDMO) in the microbiome space as Synbiotic Health spins off NoviaHealth, with a new facility in Madison, Wisconsin.

NoviaHealth LLC will provide probiotic concentrates, custom probiotic blends, and turn-key contract development and manufacturing services to the dietary supplement market.

The company has spun off from Nebraska-based Synbiotic Health, which itself was founded in 2018 by four scientific luminaries from the probiotic and microbiome field, including Dr Robert Hutkins and Dr Andy Benson (University of Nebraska-Lincoln’s Food for Health Center), Dr Jens Walter (APC Microbiome Ireland, University College Cork), and Dr Tom Burkey (University of Nebraska-Lincoln).

Synbiotic Health will continue to function as an independent company providing microbiome R&D services, according to a press release.

CDMO services

NoviaHealth will have the exclusive right to commercialize future Synbiotic Health discoveries, including new strains and other intellectual property. The new company will operate from laboratories, offices, and a new manufacturing facility in Madison, WI, that is scheduled to open in the second quarter of 2024.

NoviaHealth will provide the market with benefits and services, including product concept ideation, co-development, custom formulations, and low minimum order quantities, all within a culture of operational transparency, said the company in the release.

In addition to offering all the capabilities of a leading contract development and manufacturing organization (CDMO), NoviaHealth will also provide the Ecologically Advanced Probiotics iVS-1 and iVE-15, the legacy products of Synbiotic Health.

Additional clinically documented and undocumented probiotic strains will also be offered, as well as new probiotic solutions developed by the Madison R&D team. Targeted health areas for the full NoviaHealth strain portfolio include solutions for digestive, women’s, cognitive, children’s, early life, immunity, healthy aging, and metabolic health.

“There’s a reason “Novia” is part of our name,” said Tim Brummels, President and CEO of NoviaHealth. “It references our new way of thinking and a new way of operating. Novia is derived from the Latin word “novus”, meaning new, which reflects our constant pursuit of new ideas and innovative solutions.

“The creation of NoviaHealth represents our evolution to meet the needs of the market. As an innovative, boutique CDMO, we will cater to our customers with the services they need most: complete support from ideation to launch, a high-performing portfolio of probiotics, and a very strong commitment to personalized service.”